Dynavax Technologies Corporation’s (DVAX) Outperform Rating Reiterated at William Blair

Dynavax Technologies Corporation (NASDAQ:DVAX)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a research note issued on Wednesday. They currently have a $30.00 price objective on the biopharmaceutical company’s stock. William Blair’s target price suggests a potential upside of 74.42% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Monday, July 10th. Royal Bank Of Canada raised their target price on shares of Dynavax Technologies Corporation from $6.00 to $7.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 9th. ValuEngine lowered shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Cowen and Company restated an “outperform” rating and issued a $45.00 target price on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Finally, J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $6.00 to $27.00 in a report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Dynavax Technologies Corporation currently has a consensus rating of “Hold” and an average price target of $25.84.

Dynavax Technologies Corporation (DVAX) traded down 7.77% during mid-day trading on Wednesday, reaching $17.20. 3,851,432 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $10.50 and a 200-day moving average price of $6.66. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $18.25. The stock’s market capitalization is $854.84 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 101.98%. During the same quarter last year, the business earned ($0.75) EPS. Equities research analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation’s (DVAX) Outperform Rating Reiterated at William Blair” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/08/09/dynavax-technologies-corporations-dvax-outperform-rating-reiterated-at-william-blair.html.

A number of large investors have recently made changes to their positions in DVAX. Parametric Portfolio Associates LLC raised its stake in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 939 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Dynavax Technologies Corporation by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company’s stock worth $1,053,000 after buying an additional 6,623 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies Corporation during the first quarter worth $121,000. Falcon Point Capital LLC raised its stake in shares of Dynavax Technologies Corporation by 57.5% in the first quarter. Falcon Point Capital LLC now owns 117,568 shares of the biopharmaceutical company’s stock worth $700,000 after buying an additional 42,929 shares during the last quarter. Finally, C WorldWide Group Holding A S raised its stake in shares of Dynavax Technologies Corporation by 8.1% in the first quarter. C WorldWide Group Holding A S now owns 284,082 shares of the biopharmaceutical company’s stock worth $1,690,000 after buying an additional 21,313 shares during the last quarter. Institutional investors own 56.05% of the company’s stock.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply